Changes to the European Union pharmaceutical legislation: Implications of the ‘Pharma Review’ for biotechnology companies

Author： Liikanen Erkki  

Publisher： Palgrave Macmillan Ltd

ISSN： 1478-565X

Source： Journal of Commercial Biotechnology, Vol.11, Iss.1, 2004-10, pp. : 38-43

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

How biotechnology changes pharma R&D: a managerial perspective

By Chiesa Vittorio   Toletti Giovanni  

International Journal of Biotechnology, Vol. 5, Iss. 2, 2003-09 ,pp. : 125-140

Inderscience Publishers

Access to resources Recommend Favorite

How can pharmaceutical and biotechnology companies maintain a high profitability?

By Nickisch Klaus J   Greuel Joachim M   Bode-Greuel Kerstin M  

Journal of Commercial Biotechnology, Vol. 15, Iss. 4, 2009-10 ,pp. : 309-323

Palgrave Macmillan Ltd

Access to resources Recommend Favorite

Regulatory factors affecting the agri-food biotechnology sector in the European Union

By Diez Ma. Carmen Fernandez   Gil-Delgado Ma. Reyes Corripio  

International Journal of Biotechnology, Vol. 6, Iss. 2-3, 2004-07 ,pp. : 260-280

Inderscience Publishers

Access to resources Recommend Favorite

Comparison of the new Japanese legislation for expedited approval of regenerative medicine products with the existing systems in the USA and European Union

By  

Journal Of Tissue Engineering And Regenerative Medicine, Vol. 12, Iss. 2, 2018-02 ,pp. : e1056-e1062

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bioethical concerns in Japanese biotechnology companies

By Kato Makina  

Journal of Commercial Biotechnology, Vol. 12, Iss. 3, 2006-04 ,pp. : 205-212

Palgrave Macmillan Ltd

Access to resources Recommend Favorite